BACKGROUND: Outcome after recurrence of childhood acute myeloid leukemia (AML) is poor. We performed this study to identify prognostic factors for recurrence and for survival after recurrence of AML. METHODS: The clinical characteristics, biological features, treatment modalities, and outcomes of children with de novo AML who were enrolled on 3 consecutive clinical protocols from 1987 to 2002 at St. Jude Children's Research Hospital were studied. Regression modeling was used to identify prognostic factors for recurrence and for survival after recurrence. RESULTS: The outcome after recurrence was poor, with a 5-year survival estimate of only 23.3% +/- 5.7%. Multivariable analysis indicated that male sex (P = .005), autologous stem cell transplant before recurrence (P = .097), each additional month from diagnosis to recurrence (P = .041), and stem cell transplant after recurrence (P < .001) were associated with a better survival after recurrence, whereas M5 or M7 morphology (P = .001) were significantly predictive of a lower survival estimate after recurrence. CONCLUSIONS: Survival after recurrence was poor in children with AML. Novel therapies are urgently needed to prevent or to treat recurring AML. (c) 2006 American Cancer Society.
BACKGROUND: Outcome after recurrence of childhood acute myeloid leukemia (AML) is poor. We performed this study to identify prognostic factors for recurrence and for survival after recurrence of AML. METHODS: The clinical characteristics, biological features, treatment modalities, and outcomes of children with de novo AML who were enrolled on 3 consecutive clinical protocols from 1987 to 2002 at St. Jude Children's Research Hospital were studied. Regression modeling was used to identify prognostic factors for recurrence and for survival after recurrence. RESULTS: The outcome after recurrence was poor, with a 5-year survival estimate of only 23.3% +/- 5.7%. Multivariable analysis indicated that male sex (P = .005), autologous stem cell transplant before recurrence (P = .097), each additional month from diagnosis to recurrence (P = .041), and stem cell transplant after recurrence (P < .001) were associated with a better survival after recurrence, whereas M5 or M7 morphology (P = .001) were significantly predictive of a lower survival estimate after recurrence. CONCLUSIONS: Survival after recurrence was poor in children with AML. Novel therapies are urgently needed to prevent or to treat recurring AML. (c) 2006 American Cancer Society.
Authors: Ursula Creutzig; Martin Zimmermann; Michael N Dworzak; Brenda Gibson; Rienk Tamminga; Jonas Abrahamsson; Shau-Yin Ha; Henrik Hasle; Alexey Maschan; Yves Bertrand; Guy Leverger; Christine von Neuhoff; Bassem Razzouk; Carmelo Rizzari; Petr Smisek; Owen P Smith; Batia Stark; Dirk Reinhardt; Gertjan L Kaspers Journal: Haematologica Date: 2014-04-24 Impact factor: 9.941
Authors: David G J Cucchi; Costa Bachas; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Zinia J Kwidama; Gerrit J Schuurhuis; Yehuda G Assaraf; Valérie de Haas; Gertjan J L Kaspers; Jacqueline Cloos Journal: Cancers (Basel) Date: 2020-05-15 Impact factor: 6.639
Authors: Patrick K Campbell; Yang Zong; Shengping Yang; Sheng Zhou; Jeffrey E Rubnitz; Brian P Sorrentino Journal: Leuk Res Date: 2011-10 Impact factor: 3.156
Authors: Holly Edwards; Chengzhi Xie; Katherine M LaFiura; Alan A Dombkowski; Steven A Buck; Julie L Boerner; Jeffrey W Taub; Larry H Matherly; Yubin Ge Journal: Blood Date: 2009-07-28 Impact factor: 22.113